Health Care

Investors eye Siemens Healthineers: AI‑driven imaging, strong buybacks, ethical supply‑chain risks, and a spin‑off reshape the future of medical tech.

AbbVie’s $2B licensing deal with Gubra for weight‑loss candidate ABBV‑295, its diversified immunology‑oncology portfolio, and analysts’ focus on AI‑driven competition show how the pharma giant’s strategic partnerships and portfolio depth may secure …

Discover why analysts recommend selling Sartorius AG despite its strong biopharma foothold—currency headwinds, China slowdown, and valuation concerns highlighted in a 2026 report.

Fresenius SE & Co KGaA’s Q3 2026 earnings hit mixed but steady growth from Kabi and Helios, while cost‑saving plans and AI‑driven diagnostics position the group to weather EU reimbursement reforms and boost shareholder value.

Discover Bayer AG’s early‑stage prostate‑cancer therapy showing 18% response & 9.6‑month PFS, plus a promising PSMA‑radionuclide trial, amid volatile finances and future FDA/EMA plans.

Merck KGaA shares modestly rise amid steady R&D, strong specialty‑drug growth and low debt, suggesting resilience despite regulatory and competitive pressures.

UnitedHealth raises its dividend to $2.21, launches a $4 billion buy‑back and cuts debt to a 2.5x leverage goal—boosting shareholder value while tightening costs.

Pfizer’s new FDA approvals for BRAFTOVI and PADCEV/Keytruda promise $2.7 billion+ in 5‑year revenue, but patent risk, high‑cost logistics and payer value contracts require smart pricing, supply‑chain resilience and data‑driven care platforms to secu…

Novo Nordisk’s latest moves—Vivtex licensing for oral diabetes therapy, expanded Sogroya approval, and the Indian Extensior launch—reshape its growth strategy, offering new revenue streams amid rising competition and regulatory shifts.

Johnson & Johnson’s latest 2026 report reveals early promise for pasritamig + docetaxel in advanced prostate cancer and launches new, infection‑reduced aspiration catheters, boosting both drug and device portfolios.